REFRACTORY ANAPLASTIC LARGE CELL LYMPHOMA
Clinical trials for REFRACTORY ANAPLASTIC LARGE CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY ANAPLASTIC LARGE CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY ANAPLASTIC LARGE CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a simple vitamin pill help fight cancer?
Disease control OngoingThis study is testing whether giving vitamin D supplements to cancer patients who have low vitamin D levels can help improve their survival and delay the need for other treatments. It focuses on people newly diagnosed with certain aggressive lymphomas or a slow-growing type of le…
Matched conditions: REFRACTORY ANAPLASTIC LARGE CELL LYMPHOMA
Phase: NA • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
Virus + drug combo tested for Tough-to-Treat skin cancers
Disease control OngoingThis study is testing a two-part treatment for patients with advanced skin cancers or rare lymphomas that have not responded to other therapies. First, a modified virus is injected directly into tumors to help the immune system recognize cancer. Then, an immunotherapy drug is giv…
Matched conditions: REFRACTORY ANAPLASTIC LARGE CELL LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 24, 2026 12:03 UTC
-
New drug duo tested to fight aggressive blood cancer
Disease control OngoingThis study is testing a combination of two drugs, pembrolizumab and romidepsin, for people with a type of blood cancer called peripheral T-cell lymphoma that has come back or hasn't responded to previous treatments. The goal is to see if using these drugs together is safe and mor…
Matched conditions: REFRACTORY ANAPLASTIC LARGE CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC